Investigation of Sugammadex in Outpatient Urological Procedures

Study Procedures:

Before the cystoscopy, we will collect your basic information and medical history. We will take your vital signs and the anesthesiologist will perform routine assessments. This will take about 30-60 minutes to complete.

Before the cystoscopy, you will be given rocuronium to relax your muscles. After the procedure, you will receive either sugammadex or the standard of care to reverse the relaxation.

After you are extubated (the tube is removed from your throat), we will assess how fast the relaxation drugs the anesthesiologist gave you wear off (stop working), using a small monitoring device that will be attached to your wrist. This is the only research test that will be done right after surgery.

If you are still in the hospital 1 day after the cystoscopy, a member of the staff will ask you the series of questions. If you have been sent home, you will be called and you will complete them by phone.

Researchers will also collect information about your cystoscopy procedure and recovery from your medical record. This collection will continue for up to 1 week after surgery.

• Rocuronium (Drug), also known as Rocuronium Bromide, Zemuron: Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
• Sugammadex (Drug): Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
• Neostigmine (Drug): 70 mcg/kg by vein to reverse the muscle relaxation.
• Glycopyrrolate (Drug): 14 mcg/kg by vein to reverse the muscle relaxation.

Primary outcomes

• Muscle Recovery Time [Intraoperatively, up to 3 hours]: The primary outcome is to determine if Sugammadex can improve muscle recovery time, measured by time from administration of neuromuscular blockade reversal to train-of-four ratio of 0.9 in outpatient bladder procedures. It was assessed in the intraoperative period measuring the time from administration of reversal agent to TOF of 0.9 in minutes.

Secondary outcomes

• PostOperative Complications [Post-operatively, up to 7 days]: To determine if Sugammadex can improve post-operative complications for outpatient bladder procedures such as bladder perforation, nausea, vomiting, post-operative intubation and hospital admittance secondary to respiratory complications which was assessed uring follow ups on post-operative day 1 (POD1) and post-operative day 7 (POD7) looking for immediate postoperative complications such as bladder perforation, nausea, vomiting, postoperative intubation and hospital admittance secondary to respiratory complications and readmission within a week post-procedure for any other cause.
• Overall Recovery Time [Up to 3 hours after end of surgery]: To determine if Sugammadex can improve overall recovery time, measured by time from end of surgery to the time patient met Discharge Criteria.

Sex: All, ages: 18 Years to any

Inclusion Criteria:

1. Is scheduled to undergo cystoscopy with bladder resection procedure under general anesthesia requiring neuromuscular relaxation using rocuronium bromide to secure airway and requiring neuromuscular reversal at The University of Texas MD Anderson Cancer Center - Mays Clinic (ACB-outpatient)
2. Male or Females who are >= 18 years of age
3. Classified by the American Society of Anesthesiologists (ASA) as Class I - IV
4. Candidate for use of laryngeal mask airway (LMA)
5. Able to give consent

Exclusion Criteria:

1. Severe renal impairment as measured eGFR less than 30 per institutional laboratory.
2. Females who are pregnant or might be pregnant or are breast-feeding.
3. Females who have been diagnosed with breast cancer and currently taking Toremifene
4. Is known or suspected to have significant hepatic dysfunction, with AST \& ALT 3 times above UNL per institutional laboratory.
5. Is known or suspected to have a (family) history of malignant hyperthermia
6. Is known or suspected to have an allergy to opioids, muscle relaxants or other medications used during general anesthesia
7. Is known or suspected to have neuromuscular disorders (ex: myasthenia gravis)

Participant flow

Outcome results

• Muscle Recovery Time (Primary), Mean, minutes: Suggamadex or Treatment Group 2 +/- 0.6455; Neostigime/Glycopyrrolate or Standard of Care Group 9.24 +/- 7.8755
• PostOperative Complications (Secondary), Count of participants, Participants: Suggamadex or Treatment Group 5; Neostigime/Glycopyrrolate or Standard of Care Group 7
• Overall Recovery Time (Secondary), Mean, hours: Suggamadex or Treatment Group 2.0847 +/- 0.8742; Neostigime/Glycopyrrolate or Standard of Care Group 2.4727 +/- 2.0447

Adverse events

Time frame: 7 days post surgery

Serious adverse events by term

Other adverse events by term

• Study Protocol and Statistical Analysis Plan (PDF, 2017-10-05)

• Farzin Goravanchi, DO, Principal investigator, M.D. Anderson Cancer Center